Tisch Cancer Institute at Mount Sinai

 

WCLC 2022 Conference Coverage
T

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes With PD-L1 Blockade to Reverse Type-2 Mediated Immunosuppression

By WCLC 2022 Conference Coverage FEATURING Thomas Marron
By WCLC 2022 Conference Coverage FEATURING Thomas Marron
44 views
September 6, 2022
0 Comments
Login to view comments. Click here to Login
Videos
06:30
Tisch Cancer Institute at Mount Sinai

ASTRO 2023 Insights: "Treatment Landscape for mCRPC - Lu-177-PS…

Feat. W. Oh
10:51
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: Myeloproliferative Neoplasms

Feat. J. Mascarenhas
17:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

Feat. J. Mascarenhas
01:07
WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Cancer and Atopy: Parallel Drivers? I…

Feat. T. Marron
11:14
WCLC 2022 Conference Coverage

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Syner…

Feat. T. Marron
09:41
i3 Health

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofi…

Feat. J. Mascarenhas
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
11:42
Icahn School of Medicine at Mount Sinai

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Feat. M. Kremyanskaya
04:20
Oncology Data Advisor

The Roles of Etiology and Biopsy in Hepatocellular Carcinoma

Feat. A. Villanueva
20:43
Tisch Cancer Institute at Mount Sinai

PD-L1 Expression: Practical Implications in Advanced Stage NSCLC

Feat. F. Hirsch
07:13
ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

Feat. J. Mascarenhas
06:20
ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

Feat. J. Mascarenhas
05:04
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

Feat. A. Villanueva
15:25
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

Feat. M. Kremyanskaya
07:56
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

Feat. J. Mascarenhas
05:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

Feat. J. Mascarenhas
21:07
2021 International Congress on Myeloproliferative Neoplasms

Persistent Leukocytosis and PV Progression: Prognostic and Therapeut…

Feat. J. Mascarenhas
01:47
2021 ASCO Virtual Direct™ Highlights

2021 ASCO Summary on COVID-19 & Cancer

Feat. D. Doroshow
08:32
Tisch Cancer Institute at Mount Sinai

2020 NSCLC Update: Does PD-L1 Predict Pembrolizumab Response in Pati…

Feat. D. Doroshow
06:49
Tisch Cancer Institute at Mount Sinai

Can Pacritinib Be Used to Treat Cytokine Storm in Patients With COVI…

Feat. J. Mascarenhas
28:34
Tisch Cancer Institute at Mount Sinai

Managing Hepatocellular Carcinoma: Early Detection and Diagnosis, St…

Feat. A. Villanueva
07:57
Tisch Cancer Institute at Mount Sinai

Epidemiology of Hepatocellular Carcinoma: Disease Burden and Trends

Feat. A. Villanueva
11:35
Tisch Cancer Institute at Mount Sinai

Clinical Challenges in Management of Hepatocellular Carcinoma: Liqui…

Feat. A. Villanueva
24:22
Tisch Cancer Institute at Mount Sinai

Update on Clinical Trials in Myeloproliferative Neoplasms

Feat. J. Mascarenhas